1. Home
  2. PRLD vs CEV Comparison

PRLD vs CEV Comparison

Compare PRLD & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • CEV
  • Stock Information
  • Founded
  • PRLD 2016
  • CEV 1999
  • Country
  • PRLD United States
  • CEV United States
  • Employees
  • PRLD N/A
  • CEV N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • CEV Finance/Investors Services
  • Sector
  • PRLD Health Care
  • CEV Finance
  • Exchange
  • PRLD Nasdaq
  • CEV Nasdaq
  • Market Cap
  • PRLD 73.7M
  • CEV 71.8M
  • IPO Year
  • PRLD 2020
  • CEV N/A
  • Fundamental
  • Price
  • PRLD $0.87
  • CEV $10.27
  • Analyst Decision
  • PRLD Strong Buy
  • CEV
  • Analyst Count
  • PRLD 2
  • CEV 0
  • Target Price
  • PRLD $4.50
  • CEV N/A
  • AVG Volume (30 Days)
  • PRLD 200.4K
  • CEV 19.6K
  • Earning Date
  • PRLD 03-04-2025
  • CEV 01-01-0001
  • Dividend Yield
  • PRLD N/A
  • CEV 4.23%
  • EPS Growth
  • PRLD N/A
  • CEV N/A
  • EPS
  • PRLD N/A
  • CEV 0.36
  • Revenue
  • PRLD $3,000,000.00
  • CEV N/A
  • Revenue This Year
  • PRLD N/A
  • CEV N/A
  • Revenue Next Year
  • PRLD N/A
  • CEV N/A
  • P/E Ratio
  • PRLD N/A
  • CEV $29.36
  • Revenue Growth
  • PRLD N/A
  • CEV N/A
  • 52 Week Low
  • PRLD $0.80
  • CEV $8.83
  • 52 Week High
  • PRLD $6.80
  • CEV $10.91
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 37.59
  • CEV 59.52
  • Support Level
  • PRLD $0.87
  • CEV $10.09
  • Resistance Level
  • PRLD $1.01
  • CEV $10.30
  • Average True Range (ATR)
  • PRLD 0.08
  • CEV 0.05
  • MACD
  • PRLD -0.02
  • CEV 0.01
  • Stochastic Oscillator
  • PRLD 0.90
  • CEV 87.50

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.

Share on Social Networks: